Results 91 to 100 of about 662,207 (147)

The association between SGLT2 inhibitor use and diabetic peripheral neuropathy in type 2 diabetes: a cross-sectional study. [PDF]

Front Endocrinol (Lausanne)
Xing Y, Yin Y, Zhao Q.
europepmc   +1 more source

Combination cardiometabolic therapy in type 2 diabetes: optimizing SGLT2 inhibitor and GLP‑1 receptor agonist use. [PDF]

Curr Atheroscler Rep
Porterfield LR, Nadeem S, Swanson D, Hayek SS, Vaughan EM.   +4 more
europepmc   +1 more source

Exploratory Mediation-Informed Analysis and Dose-Response Analysis of Uric Acid Reduction and Kidney Outcomes in SGLT2 Inhibitor Therapy Compared to Allopurinol. [PDF]

Med Sci (Basel)
Jámbor T, Tallósy SP, Lantos T, Szabó A, Fejes R.   +4 more
europepmc   +1 more source

Diagnostic and Management Pitfalls of SGLT2 Inhibitor-Associated Ketoacidosis in the ICU: Lessons Following Cardiac Surgery and GLP-1 Agonist Interaction. [PDF]

Case Rep Crit Care
Pérez APG, Gutiérrez-Zárate D, Rosas-Sánchez K, Romo AM, Poblano MN.   +4 more
europepmc   +1 more source

Right Ventricular-Pulmonary Artery Coupling Predicts Early Myocardial Strain Improvement in SGLT2 Inhibitor-Treated HFrEF. [PDF]

J Saudi Heart Assoc
Hammad MA, Elgamal RM, Abouelkhir AM, Elshaer OA, Fahmy MS, Dawoud RN, Biomy R, Salama MK.   +7 more
europepmc   +1 more source

Clinical Interpretation of Modest Blood Pressure Changes After SGLT2 Inhibitor Initiation. [PDF]

J Clin Hypertens (Greenwich)
Şahin MA, Karaarslan O, Yılmaz MM, Kalçık M.   +3 more
europepmc   +1 more source

SGLT2 inhibitor use reduces progression and surgical intervention of persistent pulmonary nodules. [PDF]

Lung Cancer
Ortmeyer Welch K, McGovern KA, Chen L, Welch JC, Krouse R, Huang J, Guo K, Brown M, Singhal S, Hwang WT, Singhal S.   +10 more
europepmc   +1 more source

γδ T-cell interferon-γ production reflects metabolic improvement during SGLT2 inhibitor-based therapy in type 2 diabetes. [PDF]

Front Endocrinol (Lausanne)
Troskot Cuculić M, Sergo D, Kavazović I, Peršić V, Wensveen FM, Turk Wensveen T.   +5 more
europepmc   +1 more source

Implementing SGLT2 Inhibitor Therapy in Line with the New NICE Guidelines for Type 2 Diabetes Management. [PDF]

Diabetes Ther
Newland-Jones P, Kar P, Kelly B, Mohan R, Davies S, Diggle J, Evans M, Fernando K, Hicks D, Kanumilli N, Milne N, Patel D, Seidu S, Viljoen A, Wheeler DC, Wilding JPH.   +15 more
europepmc   +1 more source

Association Between SGLT2 Inhibitor Use and Hepatocellular Carcinoma Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis. [PDF]

Biomedicines
Hu JH, Chang ML, Huang TJ, Liu NJ, Tang JH.   +4 more
europepmc   +1 more source